841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells

• Tingting Li,
• Peng Zhang,
• Xiao Huang,
• Jing Guan,
• Hailin Wang,
• Huan Lin,
• Baohui Wang,
• Jianming Sun,
• Yujia Dan,
• Yurong Qin,
• Guojin Wu,
• Xiaofan Hou,
• Shoupeng Lai,
• Xiaoqiang Kang,
• Hong Ling

Affiliations

Tingting Li

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Peng Zhang

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Xiao Huang

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Jing Guan

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Hailin Wang

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Huan Lin

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Baohui Wang

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Jianming Sun

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Yujia Dan

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Yurong Qin

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Guojin Wu

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Xiaofan Hou

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Shoupeng Lai

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Xiaoqiang Kang

Nanjing Leads Biolabs Co., Ltd., Nanjing, China

Hong Ling

Nanjing Leads Biolabs Co., Ltd., Nanjing, China